Addex Therapeutics Ltd. (ADXN) relative valueRV
ADXN's net margin of 1746.0% ranks in the 92nd percentile of 5 Biotechnology sub-industry peers, fiscal period ending 2024-12-31.
Kresmion ranks ADXN against its industry peers from annual SEC filings and market-price snapshots.
Against 5 Biotechnology peers
| Metric | ADXN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 404K CHF | n/a | n/a | n/a |
| Revenue YoY | -74.9% | n/a | n/a | 3 |
| Gross margin | n/a | n/a | n/a | 3 |
| Operating margin | -681.8% | n/a | n/a | 4 |
| Net margin | 1746.0% | -989.3% | 92nd | 5 |
| Return on equity | 72.9% | n/a | n/a | 4 |
| P / E | n/a | n/a | n/a | n/a |
| 1 year | n/a | n/a | n/a | n/a |
Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Fiscal period ending 2024-12-31. Prices as of 2026-11-06. Every fundamental figure is one full fiscal year from one filing. Nothing is trailing twelve months and nothing is converted between currencies. P/E combines the market-price snapshot with annual earnings; one-year return uses market prices, dated separately above. 0001104659-25-049380
Peer set, 5 companies
CDIO, NIKI, CANF, EVGN, CSCIF
Left out: OSRH (period gap), PULM (period gap), SNGX (period gap), CELZ (period gap), ADAPY (no annual filing), CNSY (period gap), JAGX (period gap), PCSA (period gap), IMNN (period gap), BGMS (period gap), LGVN (period gap), ACXP (period gap), AZTR (period gap), OTLC (period gap), ALZN (period gap), RVPH (period gap), XBIO (period gap), SKYE (period gap), TCRT (period gap), APTOF.D (period gap).
What could not be compared
- 19 This company's latest fiscal year ends more than 335 days from the subject's, so it is a different economic year.
- 7 Fewer than 5 peers carry a comparable value, so no median, quartile or percentile is published.
- 6 The price series does not reach back to the start of this window.
- 5 This filer reports an ordinary share count and trades as a depositary receipt at a ratio Kresmion does not store, so price times shares would be wrong.
- 5 Reported in a different currency than the subject. A level in another currency is not comparable and is not converted here.
- 5 The filer did not report this line in the filing used.
- 2 The denominator is zero or negative, so the ratio has no meaning.
- 1 No annual filing (10-K, 20-F or 40-F) with fiscal-year figures.
- 1 No prior fiscal year in the same currency about twelve months earlier.
Free account
Open the relative value desk with a free account
An account turns this page into a research desk: thirty-one metrics over the whole peer set instead of eight, the distribution behind each median, the metric's history against the peer band, an editable peer set, and the filing behind every cell. The table above stays free.
Cite this data
Every fundamental figure is the full fiscal year reported on one annual SEC filing (10-K, 20-F or 40-F), named by accession. Peers are the company's industry group: the GICS sub-industry where the company is GICS-classified, otherwise the data vendor's industry label (the two label sets are not merged). A median, quartile or percentile is published only when at least five peers carry a comparable value, and a peer reporting in another currency is excluded from a level rather than converted. P/E combines the market-price snapshot with annual earnings; one-year return uses market prices, dated separately above.
Upstream: SEC EDGAR XBRL company facts
Kresmion, "ADXN relative value, Kresmion", data as of 2025-05-15, https://kresmion.com/tools/relative-value/ADXN. Upstream data: SEC EDGAR XBRL company facts.
Link to this data (HTML):
<a href="https://kresmion.com/tools/relative-value/ADXN">ADXN relative value, Kresmion (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures